AdGVVEGF121.10

a 121-residue isoform of vascular endothelial growth factor in phase II trials for treatment of severe coronary artery disease patients who are not candidates for bypass surgery (10/2001)

Also Known As:

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Basara, N: 1 article (06/2001)

Related Diseases

1.	Myocardial Ischemia (Ischemic Heart Diseases) 08/01/1999 - "AdGVVEGF121.10 (carrying the human vascular endothelial growth factor 121 cDNA) was administered (4 x 10(8) to 4 x 10(9.5) PU, single administration) directly to the myocardium of 11 individuals with ischemic heart disease. "
2.	Peripheral Vascular Diseases (Peripheral Vascular Disease) 06/01/2001 - "GenVec, in collaboration with Pfizer (formerly Parke-Davis), is developing AdGVVEGF121.10 (BioBypass), a gene therapy involving the 121-residue isoform of vascular endothelial growth factor (VEGF), licensed from Scios, for the potential treatment of coronary artery disease (CAD) and peripheral vascular disease (PVD) [262000]. "
3.	Coronary Artery Disease (Coronary Atherosclerosis) 06/01/2001 - "GenVec, in collaboration with Pfizer (formerly Parke-Davis), is developing AdGVVEGF121.10 (BioBypass), a gene therapy involving the 121-residue isoform of vascular endothelial growth factor (VEGF), licensed from Scios, for the potential treatment of coronary artery disease (CAD) and peripheral vascular disease (PVD) [262000]. "

Related Drugs and Biologics

1.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
2.	Protein Isoforms (Isoforms)
3.	Complementary DNA (cDNA)

Related Therapies and Procedures

1.	Therapeutics